This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks to Buy for a Santa Claus Rally


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

As the largest retail pharmacy chain in the country, Walgreen's (WAG) 7,800 stores reach more Americans than those of its rivals. At the same time, the firm is poised to benefit from one of the biggest trends in the pharmaceutical industry right now: the barrage of patent drop-offs that's threatening drugmakers' revenues for the next few years.

Combined, those factors should help Walgreen shake off the economic headwinds that are blowing its way.

Scale is Walgreen's biggest advantage. Coupled with the patent drop-off issue (which should drive higher margins through the sale of generics), size could mean higher levels of profitability than peers. But what Walgreen's peers lack in scale, they make up for in ingenuity. Rivals such as CVS Caremark (CVS) have added pharmacy benefits management to their repertoires to take a share of pharmacy sales on two fronts. Walgreen will need to keep up with new offers (such as in-store clinics) if it wants to continue its performance.

On the growth front, one major positive is saturation -- or rather the lack thereof. Despite Walgreen's huge geographic footprint, the company still hasn't reached saturation in the U.S., and it should be able to offer growth to investors for years to come. That's helped by a healthy balance sheet position with ample room to spend cash on growing a capital base.

With analyst sentiment on the rise this week, we're betting on shares ahead of Wednesday's earnings call.

Walgreen, one of the highest-yielding retail stocks, shows up on a recent list of 10 Stocks Gloomy Goldman Sachs Is Bullish On.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
SWY $35.10 -0.11%
WAG $81.65 2.05%
PAYX $52.12 0.00%
PPG $110.39 0.00%
VRSK $77.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs